Health Economics›Colorectal cancer›Maintenance after first-line therapy

Maintenance after first-line therapy

Colorectal cancer · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Capecitabine and Bevacizumab Variant #01	—	R 31 025	21d	5.6 mo	—	2	R 62 050 PFS proxy	3
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	4.9 mo	—	2	R 38 164 PFS proxy	—
Bevacizumab monotherapy Variant #01	RAS	R 19 082	14d	4.9 mo	—	2	R 38 164 PFS proxy	—
Cetuximab monotherapy Variant #07	RAS	R 11 811	180d	—	~8.1 mo	~2	~R 23 621 PFS proxy · indirect	3
Fluorouracil and Bevacizumab Variant #01	—	R 11 632	14d	5.6 mo	—	2	R 23 264 PFS proxy	2
FULV and Bevacizumab (L-Leucovorin) Variant #01 Partial	—	R 11 268	14d	~9.4 mo	—	~2	~R 22 536 PFS proxy · indirect	1
Capecitabine monotherapy Variant #01	—	R 1 039	21d	5.2 mo	—	8	R 8 309 PFS proxy	2
Observation Partial	—	—	—	3.4 mo	—	—	—	1
S-1 monotherapy Variant #01 Partial	—	—	21d	~1.7 mo	~10.5 mo	~2	—	13

9 of 9 regimens shown